累计发表SCI收录论文230余篇，中Q1区115篇，IF>10 35篇，累计影响因子IF>2100；
正在承担的课题:
1. 国家自然科学基金重点项目（82230022）脐带间充质干细胞源胞外囊泡重塑肾小管间质炎症微环境的机制研究，负责人：刘必成，金额：261万，起止年月：2023.01-2027.12。
2. 国家自然科学基金重大国际合作项目（81720108007）Exosomal miRNA介导肾小管上皮细胞-巨噬细胞对话的新机制研究, 负责人：刘必成，金额：248万元，起止年月：2018.01-2022.12。
3. 国家自然科学基金重点项目（82030024）小管上皮细胞外泌体载AKI向CKD转变中的作用机制研究，负责人：刘必成，金额：297万元，起止年月：2021.01-2025.12。
近年发表代表性论著：
1.TangTT, Wang B, Li ZL, Wen Y, Feng ST, Wu M, Liu D, Cao JY, Yin Q, Yin D, Fu YQ,Gao YM, Ding ZY, Qian JY, Wu QL, Lv LL, Liu BC. Kim-1 TargetedExtracellular Vesicles: A New Therapeutic Platform for RNAi to Treat AKI [J].Journal of the American Society of Nephrology, 2021, 32(10): 2467-2483. ( IF=14.978, Q1 )
2.CaoJY, Wang B, Tang TT, Wen Y, Li ZL, Feng ST, Wu M, Liu D, Yin D, Ma KL, Tang RN,Wu QL, Lan HY, Lv LL, Liu BC. Exosomal miR-125b-5p deriving frommesenchymal stem cells promotes tubular repair by suppression of p53 inischemic acute kidney injury [J]. Theranostics, 2021, 11(11): 5248-5266. ( IF=11.6, Q1 )
3.TangTT, Wang B, Wu M, Li ZL, Feng Y, Cao JY, Yin D, Liu H, Tang RN, Crowley SD, LvLL, Liu BC. Extracellular vesicle-encapsulated IL-10 as novelnanotherapeutics against ischemic AKI [J]. Science Advances, 2020, 6(33):eaaz0748. ( IF=14.957, Q1 )
4.TangTT, Lv LL, Wang B, Cao JY, Feng Y, Li ZL, Wu M, Wang FM, Wen Y, Zhou LT, Ni HF,Chen PS, Gu N, Crowley SD, Liu BC. Employing Macrophage-Derived Microvesiclefor Kidney-Targeted Delivery of Dexamethasone: An Efficient TherapeuticStrategy against Renal Inflammation and Fibrosis [J]. Theranostics, 2019,9(16): 4740-4755. ( IF=11.6, Q1 )
5.Lv LL,Feng Y, Wu M, Wang B, Li ZL, Zhong X, Wu WJ, Chen J, Ni HF, Tang TT, Tang RN,Lan HY, Liu BC. Exosomal miRNA-19b-3p of tubular epithelial cellspromotes M1 macrophage activation in kidney injury [J]. Cell Death andDifferentiation, 2020, 27(1): 210-226. ( IF=12.067, Q1)
6.ChenN, Hao C, Liu BC, Lin H, Wang C, Xing C, Liang X, Jiang G, Liu Z, Li X,Zuo L, Luo L, Wang J, Zhao M, Liu Z, Cai GY, Hao L, Leong R, Wang C, Liu C,Neff T, Szczech L, Yu KHP. Roxadustat Treatment for Anemia in PatientsUndergoing Long-Term Dialysis [J]. New England Journal of Medicine, 2019, 381(11):1011-1022. ( IF=176.079, Q1)
7.Wen Y, Lu XH, Ren JF,Privratsky JR, Yang B, Rudemiller NP, Zhang J, Griffiths R, Jain MK, NedospasovSA, Liu BC, Crowley SD. KLF4 in Macrophages Attenuates TNFalpha-Mediated Kidney Injury and Fibrosis [J]. Journal of the American Societyof Nephrology, 2019, 30(10): 1925-1938. ( IF=14.978, Q1 )
8.Li ZL,Lv LL, Tang TT, Wang B, Feng Y, Zhou LT, Cao JY, Tang RN, Wu M, Liu H, CrowleySD, Liu BC. HIF-1 alpha inducing exosomal microRNA-23a expressionmediates the cross-talk between tubular epithelial cells and macrophages intubulointerstitial inflammation [J]. Kidney International, 2019, 95(2):388-404. ( IF=18.998, Q1 )
9.ZhangY, Ma KL, Gong YX, Wang GH, Hu ZB, Liu L, Lu roman', serif">( IF=14.978, Q1 )
11.Lv LL, Tang PMK, Li CJ, You YK, Li J, Huang XR,Ni J, Feng M, Liu BC, Lan HY. The pattern recognition receptor, Mincle,is essential for maintaining the M1 macrophage phenotype in acute renalinflammation [J]. Kidney International, 2017, 91(3): 587-602. ( IF=18.998, Q1 )
12.Zhang LX, Wang F, Wang L, Wang WK, Liu BC,Liu J, Chen MH, He Q, Liao YH, Yu XQ, Chen N, Zhang J, Hu Z, Liu FY, Hong DQ,Ma LJ, Liu H, Zhou XL, Chen JH, Pan L, Chen W, Wang WM, Li XM, Wang HY.Prevalence of chronic kidney disease in China: a cross-sectional survey [J].The Lancet, 2012, 379(9818): 815-822. ( IF= 202.321, Q1)
13.Wang B, Wang Y, Wen Y, Zhang YL, Ni WJ, Tang TT, Cao JY, Yin Q, Jiang W,Yin D, Li ZL, Lv LL, Liu BC.Tubular-specific CDK12 knockout causes a defect in urine concentration due topremature cleavage of the slc12a1 gene [J]. Molecular Therapy, 2022 May 16. ( IF=12.91, Q1 )
14.Tang TT,Wang B, Lv LL, Dong Z, Liu BC. Extracellular vesicles for renaltherapeutics: State of the art and future perspective. Journal of Controlled Release. 2022,349:32-50.（IF=11.467,Q1）
15.Wang B, Qian JY, Tang TT, Lin LL, Yu N, Guo HL,Ni WJ, Lv LL, Wen Y, Li ZL, Wu M, Cao JY, Liu BC. VDR/Atg3 AxisRegulates Slit Diaphragm to Tight Junction Transition via p62-MediatedAutophagy Pathway in Diabetic Nephropathy [J]. Diabetes, 2022, 70(11):2639-2651. ( IF=9.337, Q1 )
16.Gao YM, Feng ST, Wen Y, Tang TT,Wang B, Liu BC. Cardiorenalprotection of SGLT2 inhibitors-Perspectives from metabolic reprogramming. EBioMedicine. 2022, 83:104215. ( IF=11.205, Q1)
17.WangB, Li ZL, Zhang YL, Wen Y, Gao YM, Liu BC.Hypoxia and chronic kidney disease [J]. EbioMedicine, 2022, 77:103942. ( IF=11.205, Q1)
18.GaoYM, Xu G, Wang B, Liu BC. Cytokine storm syndrome in coronavirus disease2019: A narrative review [J]. Journal of Internal Medicine, 2021, 289(2):147-161. ( IF=13.068, Q1)
19.Chen J,Tang TT, Cao JY, Li ZL, Zhong X, Wen Y, Shen AR, Liu BC, Lv LL. KIM-1 augments hypoxia-induced tubulointerstitialinflammation through uptake of small extracellular vesicles by tubularepithelial cells. Molecular Therapy. 2022, S1525-0016(22)00501-9.( IF=12.91, Q1 )
20.Yin Q,Zhao YJ, Ni WJ, Tang TT, Wang Y, Cao JY, Yin D, Wen Y, Li ZL, Zhang YL, JiangW, Zhang Y, Lu XY, Zhang AQ, Gan WH, Lv LL, Liu BC, Wang B. MiR-155 deficiency protects renal tubular epithelialcells from telomeric and genomic DNA damage in cisplatin-induced acute kidneyinjury. Theranostics. 2022,12(10):4753-4766. ( IF=11.556,Q1)